中科生物(01237.HK)年度虧損擴大44.4%至9309.9萬元
格隆匯 3 月 31日丨中科生物(01237.HK)公佈,截至2020年12月31日止12個月,公司收入為人民幣4.93億元,同比減少29.03%;淨虧損為人民幣9309.9萬元,同比擴大44.40%,每股虧損為人民幣0.128元。
公吿稱,於2020年,木屋及其相關部件及構件收入仍為集團的最大收益來源。該分類的收益為人民幣3.74億元(2019年:人民幣5.679億元),主要由於北美市場之銷售受到美國商務部發起之反傾銷及反補貼調查而下跌所致。
休閒傢俱產品的總收入大幅上升25.5%至人民幣90.6百萬元(二零一九年:人民幣72.1百萬元)。主要由於園藝類產品之銷售上升所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.